{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-102137","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.251134+00:00","generated_at":"2026-05-17T02:19:14.743059+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ProMIS Neurosciences appoints Slanix Paul Alex, Pharm.D., to board of directors","bullets":["Dr. Alex is President and Portfolio Manager for Ally Bridge Group, a major shareholder; joined board effective Oct 22, 2025.","He receives initial option for 40,000 common shares vesting 25% immediately, rest over 36 months; annual fee $40,000.","Company highlights upcoming data readouts from PRECISE-AD trial (PMN310) in 2Q26 and 4Q26.","Board determined Dr. Alex is independent under Nasdaq listing standards.","Ally Bridge Group has made multiple investments in ProMIS, including July 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-102137","json":"https://secwatch.observer/filing/0001104659-25-102137.json","markdown":"https://secwatch.observer/filing/0001104659-25-102137.md","text":"https://secwatch.observer/filing/0001104659-25-102137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925102137/0001104659-25-102137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925102137/pmn-20251022x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:19:14.743059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}